NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Real World Study on the Use of Cemiplimab in Adult Patients in UK

CompletedN/A

Sponsor: Sanofi

Conditions: Cutaneous Squamous Cell Carcinoma

Interventions: No intervention

Countries: United Kingdom

The primary objective is to describe the real-world clinical effectiveness of cemiplimab in patients with locally advanced cutaneous squamous cell carcinoma (laCSCC) or metastatic cutaneous squamous cell carcinoma (mCSCC) treated in routine clinical practice.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Patients aged \>=18 years at initiation of cemiplimab.
* Patients treated with \>=1 dose of cemiplimab for laCSCC or mCSCC who were not suitable for curative surgery or curative radiation according to routine practice.
* Patients initiating treatment with cemiplimab in the UK between 2nd July 2019 and 30th November 2020.

Exclusion Criteria:

* Patients who are known to have opted out of participation in any research (as required for compliance with GDPR).
* Patients participating in any form of investigative study (e.g., clinical trials) during the post-index observation period.

Locations (1)

Reading, Berkshire, United Kingdom